Use of whole genome sequencing in surveillance of drug resistant tuberculosis
- 4 May 2018
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 16 (5) , 433-442
Abstract
Introduction: The threat of resistance to anti-tuberculosis drugs is of global concern. Current efforts to monitor resistance rely on phenotypic testing where cultured bacteria are exposed to critical concentrations of the drugs. Capacity for such testing is low in TB endemic countries. Drug resistance is caused by mutations in the Mycobacterium tuberculosis genome and whole genome sequencing to detect these mutations offers an alternative means of assessing resistance. Areas covered: The challenges of assessing TB drug resistance are discussed. Progress in elucidating the M. tuberculosis resistome and evidence of the accuracy of next generation sequencing for detecting resistance is reviewed. Expert Commentary: There are considerable advantages to using next generation sequencing for TB drug resistance surveillance. Accuracy is high for detecting resistance to the major first-line drugs but is currently lower for the second-line drugs due to our incomplete knowledge regarding resistance causing mutations. With the advances in sequencing technology and the opportunity to replace phenotypic drug susceptibility testing with safer and more cost effective methods it would appear that the question is when to implement. Current bottlenecks are sample extraction to allow whole genome sequencing directly from sputum and the lack of bioinformatics expertise in some TB endemic countries.Keywords
Funding Information
- Biotechnology and Biological Sciences Research Council (BB/R013063/1)
- Medical Research Council (MR/K000551/1 and MR/M01360X/1, MR/N010469/1, MC_PC)
This publication has 59 references indexed in Scilit:
- Inferring patient to patient transmission of Mycobacterium tuberculosisfrom whole genome sequencing dataBMC Infectious Diseases, 2013
- Putative Compensatory Mutations in the rpoC Gene of Rifampin-Resistant Mycobacterium tuberculosis Are Associated with Ongoing TransmissionAntimicrobial Agents and Chemotherapy, 2013
- New Insights into Fluoroquinolone Resistance in Mycobacterium tuberculosis: Functional Genetic Analysis of gyrA and gyrB MutationsPLOS ONE, 2012
- rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis StrainsAntimicrobial Agents and Chemotherapy, 2012
- Whole-Genome Sequencing and Social-Network Analysis of a Tuberculosis OutbreakNew England Journal of Medicine, 2011
- Polymorphisms Associated with Resistance and Cross-Resistance to Aminoglycosides and Capreomycin in Mycobacterium tuberculosis Isolates from South Korean Patients with Drug-Resistant TuberculosisJournal of Clinical Microbiology, 2010
- Fluoroquinolone Resistance in Mycobacterium tuberculosis and Mutations in gyrA and gyrBAntimicrobial Agents and Chemotherapy, 2009
- Role of embB Codon 306 Mutations in Mycobacterium tuberculosis Revisited: a Novel Association with Broad Drug Resistance and IS 6110 Clustering Rather than Ethambutol ResistanceAntimicrobial Agents and Chemotherapy, 2005
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998
- Detection of rifampicin-resistance mutations in Mycobacterium tuberculosisThe Lancet, 1993